Blood based biomarkersWhy do we want them? Exactly what do we want? How will we get it ?
Adapted from Sperling et al (2011) Alzheimer’s and dementia 7 280-92Why do we want (blood based) biomarkers ?
-1.00.60.21.41.8RelativeopticaldensityP<0.050.0 0.2 0.4 0.6 0.8 1.01 - Specificity0.00.20.40.60.81.0SensitivityROC CurveComplement Factor H (CFH)n>500Proof of a signal in blood(also complement c4 – decreased)
Biomarkers for prediction‘Conversion’, progression and sub-typeCompanion biomarkersSpecific to target/therapyBiomarkers for pathologyDiscovery by endophenotypeBiomarkers for clinical trialsStratification and experimental medicineWhat, exactly, do we want ?Biomarkers for ADnot needed, not possible
Correlation with cortical atrophyCorrelation with cognition (MMSE)Correlation with speed of declineDesign mattersIn man….W/T APP/PS1In mouse….
European Medical Information FrameworkVision: To enable and conduct novel researchinto human health by utilising human health dataat an unprecedented scale• Access to information on 40 million patients• Cohorts with samples, imaging and clinical data :• > 20,000 for dementia and metabolic biomarker discovery and validation• Linkage of clinical and omics data• Development of a secure (privacy, legal) modular platform• Continue to build a network of data sources and relevant researchhttp://www.imi.europa.eu/content/emifHow will we get biomarkers ?
EMIF – a public private partnership for data-integrationEMIF-MetabolicEMIF-ADData PrivacyAnalytical toolsSemantic IntegrationInformation standardsData access / mgmtIMI Structure and NetworkResearch TopicsEMIF governancePreventionalgorithmsPredictivescreeningRiskstratificationCall 5Call 5RiskfactoranalysisPatientgenerateddataTBDEMIF-PlatformMetabolic CNS